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Abstract: Renin–angiotensin–system (RAS) activation plays a key role in the development of 
hypertension and cardiovascular disease. Drugs that antagonize the RAS (angiotensin-converting 
enzyme [ACE] inhibitors and angiotensin receptor blockers [ARBs]) have proven clinical efficacy 
in reducing blood pressure values and cardiovascular morbidity and mortality. ACE inhibitors 
partially inhibit plasma ACE, and angiotensin II generation. Thus, ARBs, which block selectively 
type 1 angiotensin II receptor (AT1R), have been developed and used in the clinical management 
of hypertension and cardiovascular disease. Experimental and clinical trials with ARBs indicate 
that this class of drug represents an effective, safe and well tolerated therapeutic option for the 
prevention and care of hypertension, even though there is no proven superiority as compared 
to ACE inhibitors except for the better tolerability. Most ARBs may not completely inhibit the 
AT1R at the approved clinical doses. Azilsartan medoxomil is a newly approved ARB for the 
management of hypertension. This ARB induces a potent and long-lasting antihypertensive effect 
and may have cardioprotective properties. This article reviews the current evidence on the clini-
cal effectiveness of azilsartan in hypertension.
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Introduction
Hypertension is a chronic disease associated with significant cardiovascular morbidity 
and mortality. Improved control of blood pressure in patients with hypertension is a key 
requirement to reduce cardiovascular and renal morbidity and mortality.1,2 Despite the 
effectiveness of the currently available antihypertensive agents, hypertension remains 
inadequately controlled, with slightly less than half of patients who receive treatment 
successfully achieving the goals for systolic and diastolic blood pressure.3,4
The renin–angiotensin–system (RAS) plays a central role in the pathophysiology of 
hypertension, cardiovascular and renal disease.5,6 It contributes to the increase of blood 
volume and arterial pressure, to the alterations of endothelial function, vascular reactivity, 
fibrosis, tissue remodeling, oxidative stress and inflammation which may predispose to 
the development of cardiovascular disease.5–7 While there are many drug classes avail-
able to reduce blood pressure, pharmacological agents that modulate the RAS are more 
commonly chosen as the first drug or in combination therapy because of their efficacy 
and the lowest side effect profile among the antihypertensive agents. The development 
of angiotensin-converting enzyme (ACE) inhibitors has represented a cornerstone for 
the treatment of various pathological cardiovascular conditions, including hypertension. 
However ACE inhibitors only partially inhibit the formation of angiotensin II (Ang II). 
From this point of view, angiotensin-receptor blockers (ARBs) provide a more rational 
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tool to inhibit RAS activity since they block selectivity the 
coupling of Ang II to type 1 angiotensin II receptor (AT1R). 
For this reason they have been developed and increasingly 
used in the clinical management of hypertension and cardio-
vascular diseases. Among the compounds that antagonize 
the RAS, ARBs (which include several molecules such as 
losartan, candesartan cilexetil, valsartan, irbesartan, telmis-
artan, eprosartan and olmesartan medoxomil, and the newest 
azilsartan medoxomil) represent today the best-tolerated class 
among antihypertensive agents.8 The clinical efficacy of ARBs 
has been established in hypertensive patients, particularly in 
terms of reduction in cardiovascular morbidity and mortality, 
prevention and regression of end organ damage and the slow 
progression of nephropathy.
Blocking the RAS: ARBs and 
cardiovascular protection
RAS blockers provide independent actions on end-organ 
protection, beyond their blood pressure lowering effect.9 
This has been shown with both ACE inhibitors and ARBs. 
A large body of evidence indicate that ACE inhibitors are 
effective for the treatment of various pathological conditions 
including arterial hypertension, diabetes, and cardiovascular 
or cerebrovascular diseases.10–13 However ACE inhibitors 
antagonize the RAS only in part. Indeed, these drugs par-
tially inhibit plasma ACE and Ang II generation, even at 
high dosages.14 Nevertheless, Ang II can be produced by 
alternative pathways (chymases, caspases, elastases) in the 
cardiovascular system.15,16 Therefore, the selective blockers 
of the AT1R, have been developed and progressively used in 
the clinical management of hypertension and cardiovascular 
diseases. The class of ARBs includes several compounds 
that share similar effects. However, the different molecules 
may present specific pharmacokinetic and pharmocody-
namic properties. Moreover, some of the molecules may 
have ancillary effects such as the increased urinary uric acid 
excretion (losartan in particular) and may activate peroxi-
some proliferator-activated receptor (PPAR)-γ which may 
contribute to a favorable metabolic profile. This latter effect 
has been described for the ARBs telmisartan, irbesartan, 
candesartan, and losartan.17
Randomized clinical trials have proven benefits for the 
therapy with ARBs in primary and secondary prevention 
in several pathological conditions including hypertension, 
coronary artery disease, congestive heart failure, and renal 
disease. ARBs have shown cardioprotective effects in 
patients with hypertension and additional risk factors. In the 
Losartan Intervention For Endpoint Reduction (LIFE)18 the 
ARB losartan was compared to atenolol in over 9000 patients 
with moderate-to-severe hypertension and left-ventricular 
hypertrophy. Losartan improved the primary composite 
endpoint, which included cardiovascular mortality, stroke, 
and myocardial infarction, independently by blood pressure 
reduction. The losartan treatment was also associated with 
a 25% lower incidence of new-onset diabetes. This was 
observed also in the placebo-controlled Kyoto Heart Study19 
in which valsartan used as add-on therapy reduced the inci-
dence of new onset of diabetes as well as cardiovascular 
outcomes in about 3000 hypertensive patients with additional 
risk factors. A recent meta-analysis has also proven the 
effectiveness of RAS blockers in reducing the occurrence 
of new-onset diabetes. Hence the ACE inhibitors or ARBs 
should be preferred in patients with clinical conditions that 
may increase the risk of developing diabetes.20
Both hypertension and diabetes may induce renal damage 
in patients at risk for cardiovascular diseases. In turn, renal 
disease may increase the cardiovascular risk even at a preclini-
cal stage (ie, presence of microalbuminuria). Furthermore, 
diabetic nephropathy is responsible for the majority of 
end-stage renal disease in most countries. Antihypertensive 
treatment may prevent the progression of the disease. In 
particular, agents that block the RAS can delay or prevent 
the diabetic nephropathy even at the initial stages as well 
as reduce the degree of albuminuria and the progression to 
advanced renal disease. In the Randomised Olmesartan And 
Diabetes Microalbuminuria Prevention (ROADMAP) study, 
the ARB olmesartan was associated with a delayed onset of 
microalbuminuria, although the drug did not reduce the car-
diovascular complications associated with the diabetic state 
and the number of cardiovascular events.21 The ARB irbesartan 
has been shown to delay the progression from microalbuminu-
ria to overt proteinuria and to restore normoalbuminuria in a 
significant proportion of patients with hypertension and type 2 
diabetes.22 Moreover, irbesartan protected against advanced 
nephropathy in hypertensive patients with type 2 diabetes, 
independently by blood pressure control.23
Ventricular dysfunction and heart failure may develop 
in the progression of the cardiovascular disease in high car-
diovascular risk patients, which are generally older than the 
patients at the early stages of the cardiovascular continuum 
and have often several comorbidities.24 ARBs were equal to 
ACE inhibitors in reducing all-cause mortality in patients with 
left-ventricular dysfunction or heart failure postmyocardial 
infarction24–26 as well as in chronic heart failure patients.27,28
In patients at higher cardiovascular risk, ARBs have been 
shown to induce similar cardiovascular protective effects. 
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Telmisartan was proven to have cardioprotective effects in 
high cardiovascular risk patients who were intolerant to ACE 
inhibitors.29 In over 25,000 patients with coronary, periph-
eral or cerebrovascular disease and diabetes with end organ 
damage the Ongoing Telmisartan Alone and in Combination 
with Ramipril Global Endpoint Trial (ONTARGET)30 has 
shown that telmisartan had similar effect to ramipril on the 
primary composite end point (including cardiovascular death, 
myocardial infarction, stroke or hospitalization for heart 
failure) and death from any cause. This was the first trial to 
compare an ARB with the ACE inhibitor ramipril, which has 
been proven to improve cardiovascular outcomes in the HOPE 
trial.31 In hypertensive patients with a history of a cerebral 
event within the previous 24 months eprosartan showed to be 
superior to the calcium-channel blocker nitrendipine for the 
secondary prevention of morbidity and mortality after stroke.32 
However, valsartan was comparable to amlodipine on the pri-
mary composite end-point in the Valsartan Antihypertensive 
Long-term Use Evaluation (VALUE) trial which included over 
15,000 patients with hypertension and additional risk factors 
(coronary heart disease, diabetes, high cholesterol).33
Thus the clinical experience with ARBs consistently 
indicates that this class of drugs represents an effective, safe 
and well tolerated therapeutic alternative for the prevention 
and care of cardiovascular disease, even though there is no 
proven superiority as compared to ACE inhibitors except for 
the well documented better tolerability. Caution should be 
used in considering ARBs interchangeably, although a class 
effect can be advocated for the clinical effectiveness of ARBs. 
Therefore, in the clinical practice it is preferable to choose 
the ARB that is proven effective, based on specific evidence 
derived from clinical studies.
Azilsartan: evidence of effectiveness
While ARBs are effective in clinical practice and well 
tolerated, the extent to which they can reduce blood pressure   
is eventually considered insufficient and a combination 
therapy is required in a significant percentage of hypertensive 
patients.34 Moreover most ARBs may not completely inhibit 
the AT1R at the approved clinical doses.
Azilsartan medoxomil is a newly approved ARB for the 
management of hypertension. It is a prodrug that is quickly 
hydrolyzed to the active moiety azilsartan, a potent and highly 
selective ARB with estimated bioavailability of 60% and elimi-
nation half-life of 12 hours.35 Findings from pharmacokinetic 
and dose-ranging studies have assessed that the effective 
therapeutic antihypertensive dosages of azilsartan medoxomil 
in humans vary from 40 to 80 mg once daily.35 Experimental 
and clinical studies have shown that this new ARB induces a 
potent and long-lasting antihypertensive effect. In conscious 
spontaneously hypertensive rats (SHRs) and renal hypertensive 
dogs, azilsartan medoxomil induced more potent and longer-
lasting antihypertensive effects than olmesartan medoxomil, 
which is the newest to the market and has been reported to 
be most effective among ARBs in terms of blood pressure 
reduction. The persistent durability of the antihypertensive 
effects of azilsartan medoxomil may reduce the variations in 
blood pressure during the day. This may contribute potential 
protective effects on cardiovascular consequences.36
Clinical trials have compared azilsartan medoxomil with 
other ARBs in the class, by studying patients with primary 
hypertension in randomized, double-blind, multicenter studies 
using ambulatory (ABPM) and clinic blood pressure mea-
surements (Table 1). Intraclass differences in blood pressure-
lowering effects within the ARB class cannot be recognized 
using clinic blood pressure measurements and may be better 
assessed with ABPM.37 Moreover, mean 24-hour systolic 
blood pressure has been shown to correlate with cardiovascular 
morbidity in patients with hypertension.38 Phase III studies 
evaluated and compared the efficacy of 24-hour mean systolic 
blood pressure and the safety of azilsartan (80 mg once daily) 
with placebo and the maximal, approved doses of olmesartan 
Table 1 Recent studies with the novel ARB compound azilsartan medoxomil in hypertensive patients
Author Year of 
publication
Population Population 
size
Comparator Baseline 
clinic BP 
(mmHg)
Basal 24-hour 
mean BP 
(mmHg)
Δ 24-hour BP after 
treatment 
(mmHg)
white et al39 2011 Stage 1–2 
hypertension
1291 Valsartan 
(320 mg) 
Olmesartan 
(40 mg)
156 to 158/ 
92 to 93
144 to 146/ 
88 to 90
-5.4 (95% CI: -8.1 –  –2.8; 
SBP, vs valsartan)* 
-3.5 (95% CI:-6.2 –  –0.9; 
SBP, vs olmesartan)§
Sica et al40 2011 Stage 1–2 
hypertension
984 Valsartan 
(320 mg)
157.2/91.2 145.6/87.9 -2.69 (95% CI: -3.49 –  –1.5; 
DBP)*
Notes: The Δ 24-hour BP is referred to comparison with azilsartan medoxomil 80 mg; *P , 0.001; §P , 0.008.
Abbreviations: ARB, angiotensin-receptor blocker; BP, blood pressure; CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
21
Azilsartan medoxomil in hypertensionIntegrated Blood Pressure Control 2012:5
medoxomil (40 mg once daily) and valsartan (320 mg once 
daily) in hypertensive patients (stage 1–2 of hypertension) 
using ambulatory and automatically measured clinic blood 
pressure monitoring.39 Azilsartan medoxomil at a dose of 
80 mg once daily for 6 weeks showed superior efficacy to the 
top approved doses for hypertension of both valsartan and 
olmesartan. Moreover, also at the dosage of 40 mg azilsartan 
medoxomil lowered clinic systolic BP to a greater extent than 
the other ARBs, suggesting that this novel agent has a greater 
potency than these other molecules at the dosages used in the 
study. Moreover, azilsartan was well tolerated and there was no 
increase in adverse events during this short-term trial. Across 
the effective dose range azilsartan showed superior efficacy 
compared to the ARB valsartan at its maximal recommended 
dose40 without any significant increase in adverse events. In 
particular, the antihypertensive effects, safety and tolerability 
of azilsartan medoxomil were compared to those of valsar-
tan in patients with stage 1 or 2 hypertension in a 24-week 
randomized, double-blind, parallel-group, multicenter trial.40 
On the basis of either ABPM or automatically measured clinic 
blood pressure measurements azilsartan medoxomil at a dose 
of 40 mg or 80 mg once daily showed greater efficacy (about 
10% in absolute rate) than a 320 mg dose of valsartan, the 
highest approved dose for this drug.40
These findings suggest that azilsartan medoxomil can 
lower 24-hour blood pressure more effectively than maxi-
mally recommended doses of other ARBs. This suggests 
that there may be a measurable hierarchal response in the 
ARB class, as far as the blood pressure levels are considered. 
Azilsartan medoxomil is expected to be able to control the 
blood pressure for a 24-hour period, which may contribute to 
the prevention of cardiovascular events. Indeed, elevations 
in blood pressure around midnight and early morning are 
important predictors of central nervous system and cardio-
vascular outcomes in hypertensive patients.41,42
Azilsartan medoxomil is highly potent in inhibiting the 
specific binding of 125I-Sar1-Ile8-Ang II to human AT1R, 
and it is a slowly dissociating Ang II receptor blocker. Indeed 
the inhibitory effect of azilsartan medoxomil persisted after 
washout of the free compound when compared to other 
ARBs (including olmesartan, telmisartan, valsartan, and 
irbesartan) which presented attenuated inhibitory effects 
with washout. In this regard, the inhibitory effects of azil-
sartan on Ang II-induced contractile response persisted after 
washout in vascular strips and Chinese hamster ovary (CHO) 
cells which overexpress the human AT1R.43 Thus Azilsartan 
medoxomil may prove to provide a more complete antago-
nism against endogenous Ang II. This may explain at least 
in part the greater blood pressure reduction associated with 
azilsartan. However, these in vitro determinations are yet to 
be supported in the whole animal or in human studies.
Beyond blood pressure control: 
pleiotropic effects of azilsartan
Hypertension is often associated with insulin resistance 
which predisposes to the development of metabolic syndrome 
and/or diabetes. Blockade of RAS/AT1R signaling has been 
shown to improve the metabolic syndrome in clinical and 
experimental studies.44 Some ARBs including losartan, 
irbesartan, and telmisartan have been shown to improve 
insulin sensitivity in rodents and humans,45,46 suggesting the 
possible involvement of the excess of Ang II in the develop-
ment of insulin resistance. Olmesartan medoxomil produced 
dose-related improvements in the insulin sensitivity of 
SHRs.36 Candesartan cilexetil improved the insulin sensitivity 
of essential hypertensive patients.47
Most recently, azilsartan medoxomil has been proven to 
improve insulin sensitivity in hypertensive rats.36 Interestingly, 
it has been shown that azilsartan medoxomil is more effec-
tive than candesartan in reducing plasma concentrations of 
glucose and fatty acids in normotensive mice.   Furthermore 
this novel ARB decreases adipose tissue weight and adipo-
cyte size and increases adipose expression of PPAR-γ and 
its target gene adiponectin, independently of its effects on 
blood pressure and plasma insulin concentrations.48 It has 
also been shown that azilsartan medoxomil induces insulin-
sensitizing effects in obese Koletsky rats, independently 
of decreases in food intake and body weight increase or of 
the activation of adipose PPAR-γ, the master regulator of 
  adipogenesis.49 In particular Azilsartan treatment decreased 
the hyperinsulinemia, improved the homeostasis model 
assessment (HOMA-IR) index and suppressed the over-
increase in plasma glucose and insulin concentrations during 
oral glucose tolerance tests in obese Koletsky rats. In the same 
rat model, it reduced the basal plasma concentrations of glu-
cose, triglyceride, and nonesterified fatty acids (NEFA). It has 
also been reported that azilsartan medoxomil improved insu-
lin sensitivity in SHRs and reduced urinary protein excretion 
more potently than olmesartan medoxomil.37 Taken together, 
this evidence suggests the possible usefulness of azilsartan 
in the treatment of insulin resistance/metabolic syndrome, 
and its potential contribution to reduce the cardiovascular 
risk linked to glucose and lipid metabolism abnormali-
ties in high risk individuals. Indeed, azilsartan medoxomil 
modulates other metabolic functions which can be involved 
in the atherosclerotic process. In cultured preadipocytes, 
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azilsartan enhanced adipogenesis and induced the expression 
of adipokines, including leptin, adipsin, and adiponectin, 
and enhanced the expression of PPAR-α and -δ, at a greater 
extent than valsartan.50
Hypertensive and/or diabetic patients often present 
microalbuminuria or overt proteinuria which are considered 
major risk factors for progression to end-stage renal disease 
and the development of cardiovascular disease.51 Reduction 
and normalization of proteinuria by drug treatment including 
the ARBs is associated with decreased risk for adverse renal 
outcomes,52 as previously discussed. Evidence from experi-
mental studies suggest that similarly to other ARBs, azil-
sartan medoxomil may induce urinary albumin and protein 
excretion levels. This may possibly occur through the activa-
tion of several candidate mechanisms, including normaliza-
tion of glomerular capillary pressure, inhibition of podocyte 
injury, inhibition of the proliferation of mesangial cells and 
inhibition epithelial–mesenchymal transition of tubular cell, 
although the exact mechanisms are unknown.36
Azilsartan medoxomil may modulate the cell growth, as 
it is indicated by the observation that it blocked the Ang II 
-induced activation of mitogen-activated protein kinases 
in vascular smooth muscle cells. Furthermore azilsartan 
medoxomil is a potent inhibitor of vascular cell prolifera-
tion even at low dosages. This effect is also evident in cells 
lacking AT1R.50
Increased expression of plasminogen activator inhibitor 
type-I (PAI-1) in the vessel wall seems to accelerate ath-
erosclerosis and it is involved in increasing the instability 
of atherosclerotic plaque.53 Azilsartan medoxomil reduced 
the expression of PAI-1 in the aortic wall of transgenic mice 
which overexpressed PAI-1 in VSMCs and were prone to 
atherosclerosis secondary to genetically determined ApoE 
deficiency.54 This was associated with a more stable athero-
sclerotic plaque. In the same mouse model azilsartan medox-
omil reduced the PAI-1 levels also in the heart. Therefore it 
may contribute to reduce this profibrotic factor that is asso-
ciated with the negative left-ventricular remodeling and the 
development of heart failure after myocardial infarction.55
These evidence suggest that azilsartan could exert 
pleiotropic cardioprotective effects beyond the expected 
beneficial effects of the potent and sustained blood pressure-
lowering action. Specific studies will be required to support 
this hypothesis.
Conclusion
Azilsartan medoxomil is a new compound proposed for the 
treatment of stage 1–2 hypertension, with its potent blood 
pressure-lowering ability associated with considerably better 
rates of hypertension control compared with other antihy-
pertensive drugs including ARBs at standard doses. This 
may result in a better control of cardiovascular risk. In fact 
even a reduction of systolic blood pressure of 2 mmHg to 
3 mmHg or more is associated with greater cardiovascular 
risk reduction as supported by in epidemiologic reports and 
interventional trials.56
The pharmacodynamic and pharmacokinetic proper-
ties suggest that azilsartan medoxomil should be used as 
an alternative agent for mild-to-moderate hypertension, 
  particularly when other antihypertensive agents are not well 
tolerated or as an adjunctive drug in hypertensive patients not 
controlled with other antihypertensive agents. Evidence from 
experimental studies suggests that azilsartan medoxomil may 
have cardioprotective properties, through a number of other 
actions which are independent of effects on blood pressure. 
At present, there are no data available on the effects of azil-
sartan on cardiovascular morbidity and mortality as well as 
on key intermediate endpoints or disease markers.
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